Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 4/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.30 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12414703 | 1.00 | TSHR (0.36) | TSHRCYP19A1PDE4APDE4BPDE4C | |
| SCHEMBL18472040 | 0.79 | POLB (0.34) | TSHRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3744381 | 0.79 | POLB (0.34) | TSHRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21026696 | 0.79 | POLB (0.34) | TSHRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL792893 | 0.77 | ITGB1 (0.32) | TSHRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL31441632 | 0.77 | ITGB1 (0.32) | TSHRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18725504 | 0.76 | ATM (0.36) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL27358271 | 0.74 | PDE4A (0.35) | TSHRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18009175 | 0.74 | KEAP1 (0.30) | — | |
| SCHEMBL18358108 | 0.73 | TSHR (0.44) | TSHRPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | TSHR 1418/4885CYP19A1 160/4885PDE4A 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.